Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 4/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14478933 | 1.00 | BCHE (0.47) | BCHESLC6A2METAP2CYP2C9CYP2C19 | |
| SCHEMBL403707 | 0.91 | BCHE (0.45) | BCHESLC6A2METAP2KLK7KLK5 | |
| SCHEMBL14478924 | 0.91 | BCHE (0.47) | BCHESLC6A2CYP2C19KLK7KLK5 | |
| SCHEMBL402884 | 0.90 | BCHE (0.47) | BCHESLC6A2METAP2KLK7KLK5 | |
| SCHEMBL403509 | 0.84 | BCHE (0.45) | BCHEMETAP2KLK7KLK5POLB | |
| SCHEMBL12355183 | 0.84 | BCHE (0.40) | BCHESLC6A2CYP2C9CYP2C19KLK7 | |
| SCHEMBL402639 | 0.82 | SLC6A2 (0.60) | BCHESLC6A2METAP2POLBGAA | |
| SCHEMBL30039963 | 0.81 | BCHE (0.49) | BCHESLC6A2CYP2C19KLK7KLK5 | |
| SCHEMBL14362878 | 0.81 | BCHE (0.46) | BCHESLC6A2METAP2KLK7KLK5 | |
| SCHEMBL14362882 | 0.81 | BCHE (0.46) | BCHESLC6A2METAP2KLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-15 | — | — | US | disclosed |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | HPSE, HAAO, HEXD | BCHE 1419/4885SLC6A2 2728/4885METAP2 1897/4885 |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | HPSE, HAAO, HEXD | BCHE 1409/4885SLC6A2 2759/4885METAP2 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.